Open AccessInvestigation of in vitro activity of colistin and tygecyclin against Stenotrophomonas maltophilia isolates
Author(s) -
Yeliz Tanrıverdi Çaycı,
İlknur Bıyık,
Gonca Yılmaz,
Kemal Bılgın,
Asuman Bırınci
Publication year - 2021
Publication title -
deneysel ve klinik tıp dergisi/journal of experimental and clinical medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.103
H-Index - 3
eISSN - 1309-4483
pISSN - 1309-5129
DOI - 10.52142/omujecm.38.4.24
Subject(s) - stenotrophomonas maltophilia , colistin , broth microdilution , minimum inhibitory concentration , microbiology and biotechnology , ceftazidime , levofloxacin , antibiotics , antimicrobial , biology , bacteria , pseudomonas aeruginosa , genetics
Stenotrophomonas maltophilia has emerged as an important opportunistic pathogen, causing infections whose management is often problematic due to its inherent resistance to many antibiotics. In this study, we aimed to investigate the antimicrobial susceptibility of colistin and tygecyclin as an alternative treatment options for S. maltophilia infections. A total of 122 S. maltophilia isolates were tested. Minimum inhibitory concentration (MIC) values of colistin and tygecycline were determined by broth microdilution method. Susceptibility of TMP/SMX and levofloxacin (LVX) were determined by disc diffusion method and MIC value of ceftazidime (CAZ) was determined by using E-test. Out of 122 S. maltophilia isolates, 5 (4%) of them were resistant to TMP-SXM. MIC range was 0.125- >512 μg/ml and MIC50 64 μg/ml, MIC90 512 μg/ml for colistin. MIC range for tygecyclin was detected as 0.5- >8, MIC50 2 μg/ml and MIC90 8 μg/ml. Tygecyclin resistance was detected as 66.4% according to the EUCAST guideline and 13.1% according to the USA-FDA breakpoints. And colistin resistance was determined as 86.9% according to both guidelines.